IL17A and hearing loss disorder: After correcting the original P-values using the Bonferroni method, IL17 was found to decrease the risk of cisplatin-induced hearing loss in children (OR: 0.18, CI: 0.06–0.48, P < 0.001, FDR = 0.041) (Fig. 3A,B, Supplementary Table 3).